Candicidin
An antifungal antibiotic derived from Streptomyces bacteria that was used historically to treat vaginal candidiasis. It works by binding to ergosterol in fungal cell membranes, causing membrane disruption and cell death. It has largely been replaced by azole antifungals in clinical practice.
Peso molecular
1109,3000 g/mol
LogP
1,80
TPSA
364,00 Ų
Regla de cinco de Lipinski
No cumple
Áreas terapéuticas
Mecanismo de acción
Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.
Estructura 2D
Cite this structure
Embed this structure
SMILES
C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC\2CC(C(C(CC(=O)CC(CC(CC(CC(=O)CCCC(=O)CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CC(C)C(CC(=O)C3=CC=C(C=C3)N)O)O)O)O)O)C(=O)O)O)O)N)O
InChI
InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1
Molecular Formula
C59H84N2O18
HBD / HBA
11 / 20
Enlaces Rotables
10
Átomos Pesados
79
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
An antifungal antibiotic derived from Streptomyces bacteria that was used historically to treat vaginal candidiasis. It works by binding to ergosterol in fungal cell membranes, causing membrane disruption and cell death. It has largely been replaced by azole antifungals in clinical practice.
Inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking ergosterol synthesis essential for fungal cell membrane integrity.
Yes, Candicidin is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6067990. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10079874. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="candicidin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/candicidin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/candicidin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/candicidin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="candicidin"></drugfyi-drug>